503 related articles for article (PubMed ID: 17139667)
21. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles.
Cambridge G; Leandro MJ; Teodorescu M; Manson J; Rahman A; Isenberg DA; Edwards JC
Arthritis Rheum; 2006 Nov; 54(11):3612-22. PubMed ID: 17075806
[TBL] [Abstract][Full Text] [Related]
22. Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus.
Bruns A; Bläss S; Hausdorf G; Burmester GR; Hiepe F
Arthritis Rheum; 2000 Oct; 43(10):2307-15. PubMed ID: 11037891
[TBL] [Abstract][Full Text] [Related]
23. Prevalence and clinico-serological correlations of anti-alpha-enolase, anti-C1q, and anti-dsDNA antibodies in patients with systemic lupus erythematosus.
Mosca M; Chimenti D; Pratesi F; Baldini C; Anzilotti C; Bombardieri S; Migliorini P
J Rheumatol; 2006 Apr; 33(4):695-7. PubMed ID: 16583471
[TBL] [Abstract][Full Text] [Related]
24. Clinically active serologically quiescent systemic lupus erythematosus.
Gladman DD; Hirani N; Ibañez D; Urowitz MB
J Rheumatol; 2003 Sep; 30(9):1960-2. PubMed ID: 12966598
[TBL] [Abstract][Full Text] [Related]
25. Serial analysis of autoantibody responses to the collagen-like region of Clq, collagen type II, and double stranded DNA in patients with systemic lupus erythematosus.
Sjoholm AG; Martensson U; Sturfelt G
J Rheumatol; 1997 May; 24(5):871-8. PubMed ID: 9150075
[TBL] [Abstract][Full Text] [Related]
26. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
[TBL] [Abstract][Full Text] [Related]
27. Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis.
Becker-Merok A; Kalaaji M; Haugbro K; Nikolaisen C; Nilsen K; Rekvig OP; Nossent JC
Arthritis Res Ther; 2006; 8(6):R162. PubMed ID: 17062137
[TBL] [Abstract][Full Text] [Related]
28. Serum amyloid P component-DNA complexes are decreased in systemic lupus erythematosus. inverse association with anti-dsDNA antibodies.
Voss A; Nielsen EH; Svehag SE; Junker P
J Rheumatol; 2008 Apr; 35(4):625-30. PubMed ID: 18278838
[TBL] [Abstract][Full Text] [Related]
29. Prolonged remission in systemic lupus erythematosus.
Urowitz MB; Feletar M; Bruce IN; Ibañez D; Gladman DD
J Rheumatol; 2005 Aug; 32(8):1467-72. PubMed ID: 16078321
[TBL] [Abstract][Full Text] [Related]
30. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.
Lu TY; Ng KP; Cambridge G; Leandro MJ; Edwards JC; Ehrenstein M; Isenberg DA
Arthritis Rheum; 2009 Apr; 61(4):482-7. PubMed ID: 19333973
[TBL] [Abstract][Full Text] [Related]
31. Anti-NR2 glutamate receptor antibodies and cognitive function in systemic lupus erythematosus.
Hanly JG; Robichaud J; Fisk JD
J Rheumatol; 2006 Aug; 33(8):1553-8. PubMed ID: 16881112
[TBL] [Abstract][Full Text] [Related]
32. Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares.
Matrat A; Veysseyre-Balter C; Trolliet P; Villar E; Dijoud F; Bienvenu J; Fabien N
Lupus; 2011 Jan; 20(1):28-34. PubMed ID: 20943718
[TBL] [Abstract][Full Text] [Related]
33. BioPlex 2200 multiplexed system: simultaneous detection of anti-dsDNA and anti-chromatin antibodies in patients with systemic lupus erythematosus.
Bardin N; Desplat-Jego S; Daniel L; Jourde Chiche N; Sanmarco M
Autoimmunity; 2009 Jan; 42(1):63-8. PubMed ID: 19127456
[TBL] [Abstract][Full Text] [Related]
34. Anti-C1q autoantibodies in lupus nephritis: prevalence and clinical significance.
Sinico RA; Radice A; Ikehata M; Giammarresi G; Corace C; Arrigo G; Bollini B; Li Vecchi M
Ann N Y Acad Sci; 2005 Jun; 1050():193-200. PubMed ID: 16014534
[TBL] [Abstract][Full Text] [Related]
35. Routine immunologic tests in systemic lupus erythematosus: is there a need for more studies?
Esdaile JM; Joseph L; Abrahamowicz M; Li Y; Danoff D; Clarke AE
J Rheumatol; 1996 Nov; 23(11):1891-6. PubMed ID: 8923362
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study.
Petri M; Singh S; Tesfasyone H; Malik A
J Rheumatol; 2009 Nov; 36(11):2476-80. PubMed ID: 19833757
[TBL] [Abstract][Full Text] [Related]
37. Role of anti-nucleosome antibody in the diagnosis of systemic lupus erythematosus.
Su Y; Jia RL; Han L; Li ZG
Clin Immunol; 2007 Jan; 122(1):115-20. PubMed ID: 17085075
[TBL] [Abstract][Full Text] [Related]
38. Circulating anti-double-stranded DNA antibody-secreting cells in patients with systemic lupus erythematosus: a novel biomarker for disease activity.
Hanaoka H; Okazaki Y; Satoh T; Kaneko Y; Yasuoka H; Seta N; Kuwana M
Lupus; 2012 Oct; 21(12):1284-93. PubMed ID: 22740429
[TBL] [Abstract][Full Text] [Related]
39. Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period.
Steiman AJ; Gladman DD; Ibañez D; Urowitz MB
Arthritis Care Res (Hoboken); 2012 Apr; 64(4):511-8. PubMed ID: 22162433
[TBL] [Abstract][Full Text] [Related]
40. Detection of nucleosome particles in serum and plasma from patients with systemic lupus erythematosus using monoclonal antibody 4H7.
Williams RC; Malone CC; Meyers C; Decker P; Muller S
J Rheumatol; 2001 Jan; 28(1):81-94. PubMed ID: 11196548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
